Molly Ivins (born August 30, 1944 -died January 31, 2007),an American political commentator, journalist, and author based in Austin, Texas. She was a syndicated columnist with nationwide distribution; her column appeared in nearly 400 newspapers across the United States.

Her articles have appeared in 'Esquire', 'The Atlantic Monthly', 'The Nation', 'Harper's', 'The Progressive', 'The Progressive Populist', and 'Mother Jones'. She has been a commentator for 'NPR', 'The NewsHour with Jim Lehrer', and '60 Minutes'.

In 1999, Ivins was diagnosed with stage III inflammatory breast cancer. Joking about it, she said:

'One of the things I said was that I had been in great hopes I would become a better person as a result of confronting my own mortality, but it actually never happened. I didn't become a better person.'

I wanted to share something Molly wrote about her breast cancer journey.

National Cancer Institute director John Neiderhuber worries the NCI 2007 budget could be slashed by five to 10 percent. And he worries that key cancer research will inevitably come to a halt as a result.

Worries stem from budget cuts proposed by President Bush. Cuts would cost the NCI between $36 million and $4.7 billion -- but Bush reports that NCI funding has doubled in the past 10 years and would still remain relatively high. And due to the recent American Cancer Society announcement that cancer deaths dropped for the second straight year, White House spokesman Tony Fratto says, "We're proud of the significant investment that we have made in cancer research. We're also proud of the results showing that researchers are delivering on that investment."

But researchers still worry. They worry cuts will undermine their successes. They feel like the rug is being pulled out from under them, just as they are making significant progress. They suspect 95 clinical trials could be postponed or cancelled, 3,000 patients could miss the opportunity of joining a trial, and some cancers will be completely eliminated from studies.

"There is a real cost in human life," says Allen Lichter, executive vice president of the American Society of Clinical Oncology, of the more-than-monetary toll budget cuts will take on NCI research efforts.

One study already on hold, pending funding decisions, is the next phase of a study evaluating whether a class of drugs called aromatase inhibitors, can prevent breast cancer. Another research group has opted to stop studying brain tumors. This is a huge loss to patients with this type of cancer, says Lichter.

It's a huge loss to all of us really -- because cancer will affect each of us in some way, some day. And so with cut budgets come cut hopes, cut dreams, and sadly -- cut survival.

Women in England are not showing up for their annual pap tests. And their absence from this critical screening opportunity is increasing their risk of cervical cancer -- a cancer that is curable if detected early.

New figures reveal that 660,000 women between the ages of 25 and 29 are invited for screening in England. Nearly 80 percent of these women accepted their invitations and reported for their tests in 1995 -- but only 69.4 percent did so last year. Women aged 30 to 34 are also down in attendance -- by about 800 women per week. Essentially, this means about 2,000 women each year who have pre-cancerous cells are missing the chance for early detection and diagnosis.

The Department of Health, now investigating the falling figures, attributes the decline to perhaps a not-so-successful screening program, discomfort about the procedure, or fear that the experience will be embarrassing.

Physicians now have a tool that can diagnose depression in cancer patients. Patients sometimes will need additional treatment to enable them to cope with their cancer more effectively.

The problem has been that doctors might have a hard time telling what patients actually have clinical depression. The patient may be just showing normal signs of sadness, feelings which commonly result from being diagnosed with cancer.

A team from the University of Liverpool's Division of Primary Care has created this method of testing called Brief Edinburgh Depression Scale (BEDS). What this test does is assess the cancer patient's mental condition with a six-step scale. The test includes questions on worthlessness, guilt and suicidal thoughts.

Professor Mari Lloyd-Williams, lead researcher says "The effects of depression can be as difficult to cope with as the physical symptoms of a terminal illness such as cancer. Patients often feel useless, that they are to blame, and even experience suicidal thoughts during cancer - these are all signs of depression but rarely elicited."

The clinical trial that was conducted included 246 patients with advanced cancer. Twenty-five percent of those patients were shown to have depression that had previously not been diagnosed.

As evidence mounts, it's becoming more and more clear that chemo brain, a mental fogginess that can result from chemotherapy, is a real concern and not just a convenient excuse cancer patients use to explain away their flighty and forgetful tendencies. It seems the brain really can suffer cognitive damage from the poisonous drugs that fight off deadly cancer cells. And sometimes, this damage is present years after treatment.

Add to chemo brain the normal aging process as well as brain conditions such as mild cognitive impairment and even schizophrenia and the brain might not stand a chance of ever remembering anything. Unless we buy into the new concept of mental training -- somewhat like physical fitness training -- in which case we may be able to bring back a level of sharpness to our lives.

Research suggests this type of training may delay mental decline. And Betty Hall, 85, who is taking a brain fitness class at her senior living complex in Illinois, says brain-enhancing activities are definitely helping her.

Hall is participating in an eight-week program where she spends one hour per day, five days per week using a computer to match words and listen for details in stories. She says it's helping her remember where she places her keys and her grocery lists -- and it's even helping her in her bridge club.

"I've won four times out of the last five at bridge club, and I think the players are going to shoot me because I keep remembering the cards people have," she said. "It's much easier for me to concentrate . . . and I brag about it everywhere I go."

One clinical professor of neurology says brain health programs will explode over the next few years because of the stunning findings on this front. One study shows relatively short training regimens, lasting just five or six weeks, improve functioning for as long as five years. And booster sessions help advance these gains. Study participants says their everyday tasks, like managing finances, are much easier after mental workouts. Another study of the computer software Hall uses shows the program shaves an average 10 years off the mental age of users.

Not all mental training is alike, and different cognitive difficulties may call for different training protocols. But the simple fact that I can work out my brain like I can work out my body gives me hope that I can possibly reverse the effects of chemotherapy on my own foggy brain, that I can one day not worry anymore that I might find my check book in the refrigerator and my cell phone in my sock drawer. Bring on the workouts!

Thanks to Bev, my brainy friend, for this story tip!

An Arkansas woman claiming the hormone replacement drug Prempro caused her breast cancer just won her legal battle against Wyeth, the maker of the drug.

Mary Daniel was awarded $1 million in compensatory damages thanks to a Philadelphia jury decision stating Wyeth acted with malice or reckless disregard for selling Prempro -- the drug Daniels took for 16 months to relieve hot flashes. The next step for Daniels, whose husband will receive $500,000, is a hearing to consider punitive damages.

Wyeth's lawyer argues that Prempro -- a combination of estrogen and progestin -- is still prescribed to women and suggests Daniel's breast cancer was caused by other risk factors, such as family history of the disease.

Peter Augustini's wife Jodi is fighting Stage IV breast cancer. They have three children, Charles, 10, Caroline, 7 and Max, 2.

Augustini is organizing a fundraiser to benefit the research Dana Farber Cancer Institute is using to help his wife fight breast cancer. He wanted to help Jodi and others fighting her type of aggressive breast cancer, referred to as Her-2 positive breast cancer.

Augustini decided to take on a holiday, Valentines day, that some people seem to think is a commercially contrived holiday. Augustini says "This is the chance to do something meaningful".

You can purchase a three inch wooden heart for your Valentine via the Share your Heart Fundraiser. The proceeds will benefit a fund specifically set up to fund research into a cure for Her-2 neu form of breast cancer. The research involves work on a drug called herceptin, which is attracted to specific proteins found only in cancer cells in the body.

The hearts are $5 each. You can also purchase a package of 10 for $20 and a package of 25 for $40. The hearts come unpainted and ready to decorate.

Share Your Heart Valentines are available for order vial the Dale, Wheelock and Memorial School Web sites, www.medfield.net or by e-mail to paugustini@cera.com.

Radioactive cancer patients attending this weekend's Super Bowl in Miami could be in for an alarming experience when they pass through radiation detectors designed to signal the presence of dirty bombs. Such cancer patients -- who have received treatment using radioisotopes and still may have tiny amounts of radioactive material in their bodies -- may want to come armed with letters from their doctors explaining their precarious set of circumstances.

The use of radioisotopes in medicine is growing -- and so is the use of radiation detectors in our security-conscious nation, which means patients are triggering alarms when they are not even aware they are being scanned, doctors and security officials say.

Nearly 60,000 people a day in the United States undergo treatment or tests that leave traces of radioactive material in their bodies, according to the Society of Nuclear Medicine. These traces are not enough to hurt anyone, but they are enough to trigger radiation alarms for up to three months.

Radioisotopes are commonly used to diagnose and treat certain cancers and thyroid disorders, to analyze heart function, and to scan bones and lungs. And many doctors already know to equip their patients with travel cards because of the problems they can encounter in public places.

Nearly 20 million nuclear medical procedures were performed in the United States in 2005 -- up 15 percent from 2001. Clearly, the number of people who could be mistaken for terrorists is quite large. So if you are one of these people -- with the power to create a buzz in a public setting -- get your papers in order so you can quickly confirm your identity as nothing more than a cancer patient.

This year alone, 215,000 women will be diagnosed with breast cancer. And sadly, not all of them will be treated equally.

Researchers reported last Tuesday that breast cancer patients who are either obese or poor are more likely to receive lower doses of chemotherapy. This might be why some women relapse and others do not, according to the researchers whose findings appear in the Journal of Clinical Oncology.

This treatment discrepancy seems to stem from doctors who mean well and want to save certain women from severe side effects of chemotherapy. Doctors may be under-dosing obese patients, for example, because a larger dose based on weight could lead to worse side effects. There is no evidence this is true, however.

As for socioeconomic status, researchers report doctors are assuming less-educated patients won't stick with a tough course of treatment -- and so they prescribe less, in hopes patients will complete the regimen.

Researchers found that severely obese women were four times more likely to get less chemotherapy than they need. Women with less than a high school education were three times more likely to receive low doses of chemotherapy. And women living in the South were almost six times more likely to come up short on the drugs they need to save their lives.

"We have new therapies and cures out there for many forms of cancer and sadly, sometimes we're not curing people because they are not getting the full doses that should be standard," says Dr. Gary Lyman who led the study at the University of Rochester Medical Center in New York.

I just finished reading the words of Mark Raymond Clements -- and the words of his wife, Marianne, written when Mark was too ill to comment. I am overcome and overwhelmed with emotion because each string of sentences filling the pages of the Clements family homepage has touched me, inspired me, and saddened me all at the same time.

Clements was diagnosed in October 2005 with cholangiocarcinoma, a rare cancer of the bile duct normally found in people in their 70s.

"There is no known cure," writes Clements. "It does not respond well to chemotherapy. It is fast moving."

And fast moving it was. Surgery -- rarely a good option for this cancer -- was attempted but without success.

"After they opened him up, they discovered that the cancer had just spread too far," Marianne writes. "They closed him back up."

Chemotherapy came next and while there were some hopeful moments -- "overall distribution of the disease has decreased" -- the overwhelming course of Clement's disease continued on a fast track. And by June 2006, Clements realized, "the cruel reality of CANCER hits like a brick wall," when a CT scan revealed the presence of as many as 20 new tumors in his liver.

The Clements family never abandoned hope and were steadfast in their faith as cancer continued to dominate their lives. In October -- one year after diagnosis -- when Marianne believed doctors were sending a let's make you as comfortable as we can message, the family began pursuing alternative methods. But by December, when it had become clear treatment of any kind would no longer help, Mark Clements was welcomed by the loving arms of hospice -- where he remained until he passed away on January, 19, 2007. He was 40 years old.

On the very day of her husband's death, Marianne writes, "I know I am not alone in feeling complete anguish at this time. I know it will lessen over time. I know I will not understand 'why' until I'm with him again, but what I do know is that Mark loved me. He loved his children. He loved his family and friends. He will be waiting for me with our loving Father in Heaven. And we will be together again. Our Father in Heaven is aware of our pain and will comfort us still as he has through this past year."

And these are just some of the words that have has touched me, inspired me, and saddened me all at the same time.

Angelina Jolie, who told CNN host Larry King on December 18 that her 56-year-old mother was battling ovarian cancer, is now confirming that her mother passed away on Saturday afternoon.

According to a new release, Angelina Jolie and brother James Haven were with their mom, actress Marcheline Bertrand, when she died this weekend at Cedars-Sinai Medical Center. It is reported that Jolie's boyfriend, Brad Pitt, was at the hospital with Jolie and her brother.

Bertrand, divorced from Jolie's Oscar-winning actor father Jon Voight and primary caretaker of her children, had small roles in the movies Lookin' to Get Out in 1982 and The Man Who Loved Women in 1983.

A private funeral is planned -- and the family asks that donations be made to the Women's Cancer Research Institute at Cedars-Sinai.

A type of brown marine seaweed contains brown algae called poly-phenols (BAPs), that might protect against skin cancers caused by ultraviolet B (UVB) radiation. UVB radiation in sunlight is thought to be responsible for most cases of non-melanoma skin cancers diagnosed in the United States.

Research has shown that BAPs are strong antioxidants and have many anti-cancer properties. The animals that were fed the brown algae in their diet had a reduction of skin tumors up to sixty percent.

The study was led by researchers at the Ohio State University Comprehensive Cancer Center. "These compounds seemed to be dramatically effective at fairly low doses both orally and topically" says principal investigator Gary D Stoner.

We all know breast cancer strikes women -- a lot of women -- but about 1,700 men also develop the disease each year in the United States. And while their risk of diagnosis is much more hopeful than the reality facing women, men with breast cancer face their own version of a not-so-rosy reality.

According to researchers at the University of California, Irvine, men treated for breast cancer face a very real chance of getting cancer again. Their study found that 11.5 percent of men with breast cancer develop second primary cancers -- mostly in the breast, stomach, and skin -- within two months following initial treatment.

"Even more disturbing, we found that men with breast cancer are diagnosed with later-stage disease and that patients with onset of the disease at a young age are even more likely to develop a second cancer," said Hoda Anton-Culver, chief of epidemiology in the UCI School of Medicine.

In light of these findings, researchers recommend men with breast cancer be closely monitored for a second onset of cancer.

What a gift it would be if it were possible to sleep through cancer, literally sleep through the entire experience -- from diagnosis through the end of treatment -- and wake up on the other end of the bad dream. Unfortunately, this isn't possible. We must be alert and aware and active in our own plans for survival. All we are typically permitted are now-and-then naps and nighttime sleep -- if we can manage to actually sleep at night.

My sleep was never disturbed during my cancer journey. Night after night, just after my head hit my pillow, my body drifted right to sleep -- only waking for brief trips to the bathroom and to get out of bed the next day. I might have had an occasional sleepless night. But for the most part, I count myself as one lucky cancer patient, blessed with restful and regular sleep.

Not all cancer patients are privileged sleepers. And with all I was enduring during my own cancer ordeal -- emotions, hospitalizations, treatments, side effects, and pain -- it's a wonder I was able to manage so well in the sleep department.

Sleep is critical for maintaining strength and energy while fighting cancer -- while living life in general really. When nighttime sleep is disrupted, interrupted, or downright impossible, normal functioning and healing are compromised. So the quest for good, quality sleep should make its way to the top of your cancer to-do list. And if you are not sure just how to begin such a quest, consider these seven strategies for sleeping through cancer -- compliments of Marie-Helene Savard, doctoral student in psychology, and Dr. Josee Savard, associate professor and researcher of psychology at Laval University Cancer Research Center in Quebec, Canada.

• Set aside at least one hour to relax before going to bed.
• Go to bed only when you feel sleepy -- which is not the same as fatigue.
• If you can't fall asleep or can't go back to sleep after 20 or 30 minutes, get out of bed and leave the bedroom. Do something else -- and only go back to bed when you feel sleepy again. Repeat as necessary.
• Get up at the same time every day -- regardless of how much sleep you got. Use an alarm clock to wake.
• Use your bedroom only for sleep and sexual activities. Avoid reading, working, watching TV, or listening to the radio in the bedroom.
• Avoid napping. If you must take a nap, do so before 3:00 PM and for less than one hour.
• Keep realistic expectations about sleep -- avoid worrying about the amount of sleep you should have or the amount of time it takes you to fall asleep -- and try to become tolerant of your lack of sleep.

Sweet dreams.

One week ago, researchers found themselves humbled by the disappointing fact that promising cancer drug Avastin had failed to help patients with pancreatic cancer live longer. In fact, not only did the drug fail to extend survival, it actually caused adverse side effects such high blood pressure and bleeding in the stomach and intestine.

In a study of 600 patients with advanced pancreatic cancer, those who received Avastin in addition to standard chemotherapy lived for only six months -- the same amount of time as those who received chemotherapy alone.

Earlier studies predicted Avastin might improve survival. It worked in patients with advanced colorectal cancer. And so it was no surprise that crowds of pancreatic cancer patients wanted a shot at this potential wonder drug that in the end turned out -- for them -- to be not so wondrous.